# State of Oklahoma <br> SoonerCare <br> Braftovi ${ }^{\circledR}$ (Encorafenib) Prior Authorization Form 

$\qquad$ Member ID\#: $\qquad$

## Drug Information

Pharmacy billing (NDC:

## Billing Provider Information

Provider NPI: $\qquad$ Provider Name: $\qquad$

## Provider Phone:

$\qquad$ Provider Fax:

## Prescriber Information

## Prescriber NPI:

## Prescriber Name:

$\qquad$
Prescriber Phone: $\qquad$ Prescriber Fax: $\qquad$ Specialty:

## Criteria

## For Initial Authorization:

1. Please indicate the diagnosis and information:
$\square$ Unresectable or Metastatic Melanoma
A. Does member have BRAF V600E or V600K mutation? Yes $\square$ No $\square$
B. Will encorafenib be used in combination with binimetinib? Yes $\square$ No $\square$
$\square$ Advanced or Metastatic Colorectal Cancer
A. Does member have BRAF V600E mutation? Yes $\square$ No $\square$
B. Will encorafenib be used in combination with cetuximab or panitumumab? Yes $\square$ No $\square$
C. Has disease progressed following adjuvant therapy within the last 12 months? Yes $\square$ No $\square$
D. Has disease progressed following metastatic therapy? Yes $\square$ No $\square$
$\square$ Non-Small Cell Lung Cancer (NSCLC)
A. Is diagnosis metastatic NSCLC? Yes $\square$ No $\square$
B. Does member have BRAF V600E mutation? Yes $\square$ No $\square$
C. Will encorafenib be used in combination with binimetinib? Yes $\square$ No $\square$
$\square$ If answer is none of the above, please indicate diagnosis:
Additional Information:

## For Continued Authorization:

1. Date of last dose: $\qquad$
2. Does patient have any evidence of progressive disease while on encorafenib therapy? Yes $\square$ No $\square$
3. Has the member experienced any adverse drug reactions related to encorafenib therapy? Yes $\square$ If yes, please specify adverse reactions:
Additional Information:
Prescriber Signature: $\qquad$ Date:
I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

Phone: 1-800-522-0114 Option 4

## CONFIDENTIALITY NOTICE

 of the transmitted documents or to verify their destruction.